{"componentChunkName":"component---src-templates-study-details-page-js","path":"/en/study/205892","result":{"data":{"studyNotFoundJson":{"title":"Study not found","content":{"childMarkdownRemark":{"html":"<p>If you entered a web address please check it was correct.</p>\n<p>You can also try <a href=\"/en/studies\">Search Page</a> to find the study you are looking for.</p>"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"<p>A unique number for a study given by ViiV.</p>"}},"ctGov":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.</p>"}},"eudraCT":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.</p>"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT02386098","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"http://","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":"true"},"PatientLevelData":"false","SharingIpd":"None","acronym":"","allocation":"Randomized","arm_groups":[{"arm_group_label":"Arm 1: BMS-955176 + ATV + RTV + DTG","arm_group_description":"BMS-955176 at 120 mg tablet per day + Atazanavir boosted with ritonavir (ATV/r) 300/100 mg tablets per day + DTG 50 mg tablet per day, orally","arm_type":"Experimental"},{"arm_group_label":"Arm 2: TDF + ATV + RTV + DTG","arm_group_description":"TDF 300 mg tablet per day + ATV/r at 300/100 mg tablets per day + DTG 50 mg per day, orally","arm_type":"Other"},{"arm_group_label":"Arm 3: BMS-955176 + ATV + DTG","arm_group_description":"BMS-955176 at 120 mg tablet per day + ATV at 400 mg tablet per day + DTG at 50 mg tablet per day, orally","arm_type":"Experimental"},{"arm_group_label":"Arm 4: BMS-955176 + ATV + DTG","arm_group_description":"BMS-955176 at 180 mg tablet per day + ATV at 400 mg tablet per day + DTG at 50 mg tablet per day, orally","arm_type":"Experimental"},{"arm_group_label":"Arm 5: TDF + ATV + RTV + DTG","arm_group_description":"TDF 300 mg tablet per day + ATV/r at 300/100 mg tablets per day + DTG 50 mg per day, orally","arm_type":"Other"}],"assignment":"Parallel Assignment","brief_summary":"The purpose of this study is to evaluate whether the combination of BMS-955176 with atazanavir (ATV) [with or without ritonavir (RTV)] and dolutegravir (DTG) is efficacious, safe, and well-tolerated in HIV-1 infected treatment experienced adults.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Strategy-confirming study of BMS-955176 to treat HIV-1 Infected treatment-experienced adults","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"HIV infections","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:20:54","criteria":"Inclusion Criteria: - Men and non-pregnant women, at least 18 years of age - Antiretroviral treatment-experienced, defined as having documented evidence of having failed 1 or 2 regimens that include 2 or 3 classes of antiretroviral (ARV) (with or without documented resistance) - CD4+ T-cell count > 50 cells/mm3 - Screening genotype/phenotype indicating susceptibility to study drugs (unboosted ATV, FC < 2.2; DTG; TDF) Exclusion Criteria: - Antiretroviral treatment-experienced adults who have failed > 2 ARV regimens - Resistance or partial resistance to any study drug determined by tests at Screening - Historical or documented genotypic and/or phenotypic drug resistance testing showing certain resistance mutations to ATV, TDF, RAL, Protease Inhibitors, and certain TAMs - Chronic hepatitis B virus (HBV)/ hepatitis C virus (HCV) - Blood tests that indicate normal liver function - Hemoglobin < 8.0 g/dL, Platelets < 50,000 cells/mm3","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 2","display_phase_internal":"PHASE_2","display_status":"Other","display_status_internal":"RECSTATUS_OTHER","endpoint":"","enrollment":"84","exclusion":"","gender":"All","gender_based":"","gender_description":"","healthy_volunteers":"No","id":"ddb468f1-c206-579e-83f4-1d4dc3a28b97","internal":{"content":null,"contentDigest":"b6a1a54f3def4b15da2c997681a104cf","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Men and non-pregnant women, at least 18 years of age - Antiretroviral treatment-experienced, defined as having documented evidence of having failed 1 or 2 regimens that include 2 or 3 classes of antiretroviral (ARV) (with or without documented resistance) - CD4+ T-cell count > 50 cells/mm3 - Screening genotype/phenotype indicating susceptibility to study drugs (unboosted ATV, FC < 2.2; DTG; TDF) Exclusion Criteria: - Antiretroviral treatment-experienced adults who have failed > 2 ARV regimens - Resistance or partial resistance to any study drug determined by tests at Screening - Historical or documented genotypic and/or phenotypic drug resistance testing showing certain resistance mutations to ATV, TDF, RAL, Protease Inhibitors, and certain TAMs - Chronic hepatitis B virus (HBV)/ hepatitis C virus (HCV) - Blood tests that indicate normal liver function - Hemoglobin < 8.0 g/dL, Platelets < 50,000 cells/mm3","interventions":[{"arm_group_label":"Arm 1: BMS-955176 + ATV + RTV + DTG","intervention_description":"HIV Maturation Inhibitor","intervention_name":"BMS-955176","intervention_type":"Drug"},{"arm_group_label":"Arm 3: BMS-955176 + ATV + DTG","intervention_description":"HIV Maturation Inhibitor","intervention_name":"BMS-955176","intervention_type":"Drug"},{"arm_group_label":"Arm 4: BMS-955176 + ATV + DTG","intervention_description":"HIV Maturation Inhibitor","intervention_name":"BMS-955176","intervention_type":"Drug"},{"arm_group_label":"Arm 1: BMS-955176 + ATV + RTV + DTG","intervention_description":"Atazanavir","intervention_name":"Atazanavir (ATV)","intervention_type":"Drug"},{"arm_group_label":"Arm 3: BMS-955176 + ATV + DTG","intervention_description":"Atazanavir","intervention_name":"Atazanavir (ATV)","intervention_type":"Drug"},{"arm_group_label":"Arm 2: TDF + ATV + RTV + DTG","intervention_description":"Atazanavir","intervention_name":"Atazanavir (ATV)","intervention_type":"Drug"},{"arm_group_label":"Arm 5: TDF + ATV + RTV + DTG","intervention_description":"Atazanavir","intervention_name":"Atazanavir (ATV)","intervention_type":"Drug"},{"arm_group_label":"Arm 4: BMS-955176 + ATV + DTG","intervention_description":"Atazanavir","intervention_name":"Atazanavir (ATV)","intervention_type":"Drug"},{"arm_group_label":"Arm 1: BMS-955176 + ATV + RTV + DTG","intervention_description":"Ritonavir","intervention_name":"Ritonavir (RTV)","intervention_type":"Drug"},{"arm_group_label":"Arm 2: TDF + ATV + RTV + DTG","intervention_description":"Ritonavir","intervention_name":"Ritonavir (RTV)","intervention_type":"Drug"},{"arm_group_label":"Arm 5: TDF + ATV + RTV + DTG","intervention_description":"Ritonavir","intervention_name":"Ritonavir (RTV)","intervention_type":"Drug"},{"arm_group_label":"Arm 1: BMS-955176 + ATV + RTV + DTG","intervention_description":"Dolutegravir","intervention_name":"Dolutegravir (DTG)","intervention_type":"Drug"},{"arm_group_label":"Arm 3: BMS-955176 + ATV + DTG","intervention_description":"Dolutegravir","intervention_name":"Dolutegravir (DTG)","intervention_type":"Drug"},{"arm_group_label":"Arm 2: TDF + ATV + RTV + DTG","intervention_description":"Dolutegravir","intervention_name":"Dolutegravir (DTG)","intervention_type":"Drug"},{"arm_group_label":"Arm 5: TDF + ATV + RTV + DTG","intervention_description":"Dolutegravir","intervention_name":"Dolutegravir (DTG)","intervention_type":"Drug"},{"arm_group_label":"Arm 4: BMS-955176 + ATV + DTG","intervention_description":"Dolutegravir","intervention_name":"Dolutegravir (DTG)","intervention_type":"Drug"},{"arm_group_label":"Arm 2: TDF + ATV + RTV + DTG","intervention_description":"Tenofovir","intervention_name":"Tenofovir (TDF)","intervention_type":"Drug"},{"arm_group_label":"Arm 5: TDF + ATV + RTV + DTG","intervention_description":"Tenofovir","intervention_name":"Tenofovir (TDF)","intervention_type":"Drug"}],"interventional_subtype":"Treatment","is_fda_regulated":true,"is_high_value":false,"is_ind_study":true,"keywords":[],"last_follow_up_date":"06/07/2017 00:00:00","links":[],"locations":[{"City":"Bangkok","Latitude":"13.7401666","CountryDisplay":"Thailand","Longitude":"100.5352367","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"10330","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Kaohsiung","Latitude":"22.6272784","CountryDisplay":"Taiwan","Longitude":"120.3014353","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"81346","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Los Angeles","Latitude":"34.1220545","CountryDisplay":"United States","Longitude":"-118.2935891","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90027","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Lima","Latitude":"-12.0320387","CountryDisplay":"Peru","Longitude":"-77.0868865","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"Lima 31","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Barranquilla","Latitude":"11.0041072","CountryDisplay":"Colombia","Longitude":"-74.8069813","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":null,"StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Indianapolis","Latitude":"39.7794767","CountryDisplay":"United States","Longitude":"-86.1700894","Name":"GSK Investigational Site","StateDisplay":"Indiana","PostalCode":"46202","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Tembisa","Latitude":"-26.0169333","CountryDisplay":"South Africa","Longitude":"28.2117257","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"1632","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Tampa","Latitude":"28.0133862","CountryDisplay":"United States","Longitude":"-82.5077593","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33614","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Vancouver","Latitude":"49.278915","CountryDisplay":"Canada","Longitude":"-123.12909","Name":"GSK Investigational Site","StateDisplay":"British Columbia","PostalCode":"V6Z 2C7","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Córdoba","Latitude":"-31.4200833","CountryDisplay":"Argentina","Longitude":"-64.1887761","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"X5000JJS","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Westdene","Latitude":"-26.1809096","CountryDisplay":"South Africa","Longitude":"27.986402","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"2092","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Irkutsk","Latitude":"52.3537359","CountryDisplay":"Russia","Longitude":"104.3096191","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"664035","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Toronto","Latitude":"43.6584136","CountryDisplay":"Canada","Longitude":"-79.3891419","Name":"GSK Investigational Site","StateDisplay":"Ontario","PostalCode":"M5G 2N2","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Montreal","Latitude":"45.5152072","CountryDisplay":"Canada","Longitude":"-73.5562284","Name":"GSK Investigational Site","StateDisplay":"Québec","PostalCode":"H2L 5B1","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Palm Springs","Latitude":"33.8613433","CountryDisplay":"United States","Longitude":"-116.5727815","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"92262","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Lima","Latitude":"-12.0463731","CountryDisplay":"Peru","Longitude":"-77.042754","Name":"GSK Investigational Site","StateDisplay":"Lima","PostalCode":"1","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Krasnodar","Latitude":"45.0403106","CountryDisplay":"Russia","Longitude":"38.9812579","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"350015","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"New Haven","Latitude":"41.3064267","CountryDisplay":"United States","Longitude":"-72.9310217","Name":"GSK Investigational Site","StateDisplay":"Connecticut","PostalCode":"06520","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Providencia, Santiago de Chile","Latitude":"-33.4314474","CountryDisplay":"Chile","Longitude":"-70.6093325","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"7500922","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"St. Petersburg","Latitude":"59.9126905","CountryDisplay":"Russia","Longitude":"30.2945611","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"190103","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Sydney","Latitude":"-33.8825595","CountryDisplay":"Australia","Longitude":"151.2131584","Name":"GSK Investigational Site","StateDisplay":"New South Wales","PostalCode":"2010","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"DF","Latitude":"19.2871869","CountryDisplay":"Mexico","Longitude":"-99.1705253","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"14000","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Mar del Plata","Latitude":"-38.0054771","CountryDisplay":"Argentina","Longitude":"-57.5426106","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"B7600FZN","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Tulsa","Latitude":"36.1005816","CountryDisplay":"United States","Longitude":"-95.9251211","Name":"GSK Investigational Site","StateDisplay":"Oklahoma","PostalCode":"74135","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Atlanta","Latitude":"33.7440941","CountryDisplay":"United States","Longitude":"-84.377861","Name":"GSK Investigational Site","StateDisplay":"Georgia","PostalCode":"30312","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"New York","Latitude":"40.7916407","CountryDisplay":"United States","Longitude":"-73.9447994","Name":"GSK Investigational Site","StateDisplay":"New York","PostalCode":"10029","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Buenos Aires","Latitude":"-34.6036844","CountryDisplay":"Argentina","Longitude":"-58.3815591","Name":"GSK Investigational Site","StateDisplay":"Buenos Aires","PostalCode":"1202","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Mexico City","Latitude":"19.4173639","CountryDisplay":"Mexico","Longitude":"-99.1594532","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"06700","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Orlando","Latitude":"28.5747416","CountryDisplay":"United States","Longitude":"-81.3949264","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"32804","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Santiago","Latitude":"-33.4488897","CountryDisplay":"Chile","Longitude":"-70.6692655","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"8360159","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Taipei","Latitude":"25.0421407","CountryDisplay":"Taiwan","Longitude":"121.5198716","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"100","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Ekaterinburg","Latitude":"56.8169807","CountryDisplay":"Russia","Longitude":"60.5695221","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"620102","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Rosario","Latitude":"-32.9622313","CountryDisplay":"Argentina","Longitude":"-60.6255364","Name":"GSK Investigational Site","StateDisplay":"Santa Fe","PostalCode":"2000","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Dallas","Latitude":"32.7962048","CountryDisplay":"United States","Longitude":"-96.7694752","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"75246","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Guadalajara","Latitude":"20.6850452","CountryDisplay":"Mexico","Longitude":"-103.342846","Name":"GSK Investigational Site","StateDisplay":"Jalisco","PostalCode":"44280","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Lima","Latitude":"-12.0471913","CountryDisplay":"Peru","Longitude":"-77.0427055","Name":"GSK Investigational Site","StateDisplay":"Lima","PostalCode":"Lima 11","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"West Palm Beach","Latitude":"26.7153474","CountryDisplay":"United States","Longitude":"-80.0533253","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33401","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Beverly Hills","Latitude":"34.0661071","CountryDisplay":"United States","Longitude":"-118.3841777","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90211","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Santiago","Latitude":"-33.4488897","CountryDisplay":"Chile","Longitude":"-70.6692655","Name":"GSK Investigational Site","StateDisplay":"Región Metro De Santiago","PostalCode":"8330074","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Winnipeg","Latitude":"49.9042982","CountryDisplay":"Canada","Longitude":"-97.1585239","Name":"GSK Investigational Site","StateDisplay":"Manitoba","PostalCode":"R3A 1R9","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Bogota","Latitude":"4.6292618","CountryDisplay":"Colombia","Longitude":"-74.0740729","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"111311","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Port Elizabeth","Latitude":"-33.9316236","CountryDisplay":"South Africa","Longitude":"25.5977123","Name":"GSK Investigational Site","StateDisplay":"Eastern Cape","PostalCode":"6001","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Buenos Aires","Latitude":"-34.6213576","CountryDisplay":"Argentina","Longitude":"-58.3773266","Name":"GSK Investigational Site","StateDisplay":"Buenos Aires","PostalCode":"1141","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Ciudad Autónoma de Buenos Aires","Latitude":"-34.6036844","CountryDisplay":"Argentina","Longitude":"-58.3815591","Name":"GSK Investigational Site","StateDisplay":"Buenos Aires","PostalCode":"C1405CKC","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Juarez","Latitude":"31.7296342","CountryDisplay":"Mexico","Longitude":"-106.4656184","Name":"GSK Investigational Site","StateDisplay":"Chihuahua","PostalCode":"32330","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Mexico City","Latitude":"19.2892862","CountryDisplay":"Mexico","Longitude":"-99.1580693","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"CP 14080","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Darlinghurst","Latitude":"-33.8780176","CountryDisplay":"Australia","Longitude":"151.2204441","Name":"GSK Investigational Site","StateDisplay":"New South Wales","PostalCode":"2010","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Montreal","Latitude":"45.5179048","CountryDisplay":"Canada","Longitude":"-73.558878","Name":"GSK Investigational Site","StateDisplay":"Québec","PostalCode":"H2L 4P9","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Cali","Latitude":"3.4516467","CountryDisplay":"Colombia","Longitude":"-76.5319854","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":null,"StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Darlinghurst, Sydney","Latitude":"-33.8780176","CountryDisplay":"Australia","Longitude":"151.2204441","Name":"GSK Investigational Site","StateDisplay":"New South Wales","PostalCode":"2010","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Moscow","Latitude":"55.766642","CountryDisplay":"Russia","Longitude":"37.7393379","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"105275","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Lima","Latitude":"-12.0597607","CountryDisplay":"Peru","Longitude":"-77.0456973","Name":"GSK Investigational Site","StateDisplay":"Lima","PostalCode":"Lima 14","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Toronto","Latitude":"43.7215696","CountryDisplay":"Canada","Longitude":"-79.3768256","Name":"GSK Investigational Site","StateDisplay":"Ontario","PostalCode":"M4N 3M5","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Bogotá","Latitude":"4.7109886","CountryDisplay":"Colombia","Longitude":"-74.072092","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":null,"StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Oaxaca","Latitude":"17.0637447","CountryDisplay":"Mexico","Longitude":"-96.7253164","Name":"GSK Investigational Site","StateDisplay":"Oaxaca","PostalCode":"68000","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Vancouver","Latitude":"49.2810099","CountryDisplay":"Canada","Longitude":"-123.1287947","Name":"GSK Investigational Site","StateDisplay":"British Columbia","PostalCode":"V6Z 1Y6","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Distrito Federal","Latitude":"19.3806445","CountryDisplay":"Mexico","Longitude":"-99.1791765","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"03720","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Fort Lauderdale","Latitude":"26.1897731","CountryDisplay":"United States","Longitude":"-80.1037721","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33308","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"San Juan","Latitude":"18.4465407","CountryDisplay":"Puerto Rico","Longitude":"-66.067938","Name":"GSK Investigational Site","StateDisplay":"Puerto Rico","PostalCode":"00909-1711","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Austin","Latitude":"30.2961708","CountryDisplay":"United States","Longitude":"-97.7389543","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"78705","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Deland","Latitude":"29.0128283","CountryDisplay":"United States","Longitude":"-81.3729372","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"32720","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Montreal","Latitude":"45.4745831","CountryDisplay":"Canada","Longitude":"-73.5980739","Name":"GSK Investigational Site","StateDisplay":"Québec","PostalCode":"H4A 3J1","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Bloemfontein","Latitude":"-29.13184","CountryDisplay":"South Africa","Longitude":"26.1950214","Name":"GSK Investigational Site","StateDisplay":"Free State","PostalCode":"9301","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Bronx","Latitude":"40.8723987","CountryDisplay":"United States","Longitude":"-73.8713099","Name":"GSK Investigational Site","StateDisplay":"New York","PostalCode":"10467","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"}],"masking":"","maximum_age_raw":"N/A","maximum_age":"N/A","minimum_age":"18","minimum_age_raw":"18 years","modified_date":"10/01/2018 22:43:11","number_of_arms":"5","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"A Phase 2b Randomized, Active-Controlled, Staged, Open-label Trial to Investigate Safety and Efficacy of BMS-955176 in Combination with Dolutegravir and Atazanavir (with or without Ritonavir) in Treatment-Experienced HIV-1 infected Adults","org_study_id":"205892","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Terminated","oversight_info":{"exported_from_us":"","fda_regulated_device":"No","fda_regulated_drug":"Yes","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"2","primary_compl_date":"06/07/2017 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"The proportion of subjects with plasma HIV 1 RNA less than 40 c/mL at Week 24","outcome_time_frame":"Week 24","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[{"id":"AI468-048","id_type":"Other Identifier","id_domain":"Bristol-Myers Squibb"}],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"The antiviral efficacy of BMS-955176 Arms, and the TDF-containing Arms (TDF + ATV/r + DTG), by determining the proportion of treatment-experienced subjects with plasma HIV-1 RNA less than 40 c/mL","outcome_time_frame":"At Weeks 48 and 96","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"The antiviral efficacy of BMS-955176 Arms, and the TDF-containing Arms, by determining the proportion of treatment-experienced subjects with plasma HIV-1 RNA less than 200 c/mL","outcome_time_frame":"At Weeks 24,48 and 96","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"The emergence of HIV drug resistance in samples selected for drug resistance testing","outcome_time_frame":"At Weeks 24,48 and 96","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Efficacy of BMS-955176 Arms, and the TDF-containing Arms, by using the mean changes from baseline in log10 HIV-1 RNA, CD4+ T-cell counts, and percentage of CD4+ T cells","outcome_time_frame":"At Weeks 24,48 and 96","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Safety and tolerability of BMS-955176 in treatment-experienced subjects by measuring frequency of serious adverse events (SAEs) and adverse events (AEs) leading to discontinuation","outcome_time_frame":"At Weeks 24,48 and 96","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Disease progression as measured by the occurrence of new Acquired immune deficiency syndrome (AIDS) defining events (CDC Class C events)","outcome_time_frame":"At Weeks 24,48 and 96","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Area under the concentration-time curve (AUC) of BMS-955176","outcome_time_frame":"At Week 24","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Maximum observed concentration (Cmax) of BMS-955176","outcome_time_frame":"At Week 24","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["GlaxoSmithKline"]},"start_date":"07/08/2015 00:00:00","study_type":"Interventional","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":false}},"pageContext":{"studyId":"205892"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}